SNP rs13194504 AA genotype is associated with the severity of tardive dyskinesia

For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but not associated with its occurrence, a recent study shows published in Human psychopharmacology: clinical and experimental.

Ruoyu Wang, from the Center for Addiction and Mental Health in Toronto, and colleagues tested SNPs rs13194504 and rs210133 for the association with the occurrence and severity of TD among 172 patients with schizophrenia recruited into four studies at three clinical sites in Canada and the United States. United States.

The researchers found that there was an association for the rs13194504 AA genotype with reduced severity of TD, as measured by the Abnormal Involuntary Movement Scale (AIMS), but not for the occurrence of TD. No significant association was seen for rs210133 with the occurrence of TD or AIMS scores.

“Our results suggest that the SNP rs13194504 AA genotype may be associated with reduced severity of TD, indicating a potential protective effect against TD,” the authors write.

Several authors revealed ties to the pharmaceutical industry.

© 2024 Health Day. All rights reserved.